JP2021504312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504312A5 JP2021504312A5 JP2020526986A JP2020526986A JP2021504312A5 JP 2021504312 A5 JP2021504312 A5 JP 2021504312A5 JP 2020526986 A JP2020526986 A JP 2020526986A JP 2020526986 A JP2020526986 A JP 2020526986A JP 2021504312 A5 JP2021504312 A5 JP 2021504312A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- solid dosage
- oral solid
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008184 oral solid dosage form Substances 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 18
- 239000007787 solid Substances 0.000 claims 12
- 239000008187 granular material Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 230000001404 mediated Effects 0.000 claims 7
- 239000004094 surface-active agent Substances 0.000 claims 7
- 102000003827 Plasma kallikrein Human genes 0.000 claims 6
- 108090000113 Plasma kallikrein Proteins 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- 239000011230 binding agent Substances 0.000 claims 5
- 239000002775 capsule Substances 0.000 claims 5
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 201000011190 diabetic macular edema Diseases 0.000 claims 4
- 239000005720 sucrose Substances 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 108010010803 Gelatin Proteins 0.000 claims 3
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical class OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- -1 dextrate Substances 0.000 claims 3
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 3
- 239000008273 gelatin Substances 0.000 claims 3
- 229920000159 gelatin Polymers 0.000 claims 3
- 235000019322 gelatine Nutrition 0.000 claims 3
- 235000011852 gelatine desserts Nutrition 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 230000035699 permeability Effects 0.000 claims 3
- 230000002207 retinal Effects 0.000 claims 3
- 235000020945 retinal Nutrition 0.000 claims 3
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 claims 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims 2
- 206010019860 Hereditary angioedema Diseases 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 claims 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims 1
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical class OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 claims 1
- 229920001817 Agar Polymers 0.000 claims 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 claims 1
- 239000005995 Aluminium silicate Substances 0.000 claims 1
- 206010003246 Arthritis Diseases 0.000 claims 1
- 241000416162 Astragalus gummifer Species 0.000 claims 1
- 239000004135 Bone phosphate Substances 0.000 claims 1
- 229960003563 Calcium Carbonate Drugs 0.000 claims 1
- 229940078495 Calcium phosphate dibasic Drugs 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 208000009190 Disseminated Intravascular Coagulation Diseases 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- 229960002737 Fructose Drugs 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000001083 Kidney Disease Diseases 0.000 claims 1
- 229960001375 Lactose Drugs 0.000 claims 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 1
- 229960001021 Lactose Monohydrate Drugs 0.000 claims 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 210000004165 Myocardium Anatomy 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010029149 Nephropathy Diseases 0.000 claims 1
- 206010029151 Nephropathy Diseases 0.000 claims 1
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 claims 1
- 229940069328 Povidone Drugs 0.000 claims 1
- 208000004644 Retinal Vein Occlusion Diseases 0.000 claims 1
- 241000978776 Senegalia senegal Species 0.000 claims 1
- 206010040070 Septic shock Diseases 0.000 claims 1
- 229940005550 Sodium alginate Drugs 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 229940046009 Vitamin E Drugs 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- XYFGTTCGHCGTDZ-ZRVLSRDKSA-N [(2R,3S,4S,5R,6R)-6-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl hexadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 XYFGTTCGHCGTDZ-ZRVLSRDKSA-N 0.000 claims 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2S,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 claims 1
- ZZXIXQRNGZFIQT-JSJITEFISA-N [(2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl (Z)-octadec-9-enoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O ZZXIXQRNGZFIQT-JSJITEFISA-N 0.000 claims 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 230000001058 adult Effects 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 235000012211 aluminium silicate Nutrition 0.000 claims 1
- 229940116224 behenate Drugs 0.000 claims 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 claims 1
- 201000004569 blindness Diseases 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 229960001714 calcium phosphate Drugs 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 235000011132 calcium sulphate Nutrition 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000271 cardiovascular Effects 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 229920001531 copovidone Polymers 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-M erucate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC([O-])=O DPUOLQHDNGRHBS-KTKRTIGZSA-M 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229960000829 kaolin Drugs 0.000 claims 1
- 239000000832 lactitol Substances 0.000 claims 1
- 229960003451 lactitol Drugs 0.000 claims 1
- 235000010448 lactitol Nutrition 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 125000001095 phosphatidyl group Chemical class 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 150000003019 phosphosphingolipids Chemical class 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000019814 powdered cellulose Nutrition 0.000 claims 1
- 229920003124 powdered cellulose Polymers 0.000 claims 1
- 230000000241 respiratory Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 229940086735 succinate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 229960001367 tartaric acid Drugs 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 150000003712 vitamin E derivatives Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 COCc1c[n](Cc2ccc(C*C=CC=CC(*)=O)cc2)cc1C(NCc(nccc1OC)c1F)=O Chemical compound COCc1c[n](Cc2ccc(C*C=CC=CC(*)=O)cc2)cc1C(NCc(nccc1OC)c1F)=O 0.000 description 1
Claims (16)
- 前記剤形中の前記式Aの化合物の固体形態の量が、0.1mg〜1,000mgであり、及び/又は
前記式Aの化合物の固体形態が、前記経口固体剤形の総重量に対して1wt%〜70wt%の量で存在する、請求項1に記載の経口固体剤形。 - 以下をさらに含む、請求項1又は2に記載の経口固体剤形:
(i)結合剤、
任意選択的に、前記結合剤が、メチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポビドン、コポビドン、ゼラチン、アラビアゴム、エチルセルロース、ポリビニルアルコール、デンプン、アルファ化デンプン、寒天、トラガント及びアルギン酸ナトリウムのうちの1つ以上を含み、及び/又は
前記結合剤が、前記経口固体剤形の総重量に対して0.1wt%〜30wt%の量で存在し、及び/又は
前記式Aの化合物と前記結合剤との重量比が、1:0.01〜1:1である、
及び/又は
(ii)希釈剤、
任意選択的に、前記希釈剤が、炭酸カルシウム、リン酸カルシウム二塩基性、リン酸カルシウム三塩基性、硫酸カルシウム、微結晶セルロース、粉末セルロース、デキストレート、デキストリン、デキストロース賦形剤、フルクトース、カオリン、ラクチトール、ラクトース、ラクトース一水和物、マンニトール、ソルビトール、マルチトール、デンプン、アルファ化デンプン及びスクロースのうちの1つ以上を含み、及び/又は
前記希釈剤が、前記経口固体剤形の総重量に対して1wt%〜99wt%の量で存在し、及び/又は
前記式Aの化合物と前記希釈剤との重量比が、1:0.1〜1:500である、
及び/又は
(iii)崩壊剤、
及び/又は
(iv)滑沢剤及び/又は流動促進剤、
及び/又は
(v)酸、
任意選択的に、前記酸が、マレイン酸、酒石酸、コハク酸及びクエン酸のうちの1つ以上を含み、及び/又は
前記酸が、前記経口固体剤形の総重量に対して1wt%〜40wt%の量で存在し、及び/又は
前記式Aの化合物と前記酸との重量比が、1:0.1〜1:2である、
及び/又は
(vi)界面活性剤、
任意選択的に、前記界面活性剤が、ラウリル硫酸ナトリウム及び/又はTween 80を含み、及び/又は
前記界面活性剤が、前記経口固体剤形の総重量に対して1wt%〜20wt%の量で存在し、及び/又は
前記式Aの化合物と前記界面活性剤との重量比が、1:0.01〜1:1である、
及び/又は
(vii)コーティング、
任意選択的に、前記コーティングが、腸溶性コーティングである、
並びに/又は
(viii)1つ以上のさらなる有効成分。 - 以下をさらに含む、請求項1又は2に記載の経口固体剤形:
脂質賦形剤、
任意選択的に、前記脂質賦形剤が、ステアリン酸スクロース、パルミチン酸スクロース、ラウリン酸スクロース、ベヘン酸スクロース、オレイン酸スクロース、エルカ酸スクロースなどのスクロース脂肪酸エステル、及びこれらの混合物;リン脂質誘導体、ホスファチジル誘導体、グリコシルセラミド誘導体、脂肪酸誘導体、非イオン性界面活性剤、ビタミンEトコフェリルスクシネートポリエチレングリコール(TPGS)誘導体、モノオレイン酸グリセリル、Gelucire(商標登録)シリーズの界面活性剤、グリセリド誘導体など及びこれらの混合物のうちの1つ以上を含み、及び/又は
前記脂質賦形剤が、前記経口固体剤形の総重量に対して10wt%〜99%の量で存在し、及び/又は
前記式Aの化合物と前記脂質賦形剤との重量比が、1:0.1〜1:100である、
及び/又は
コーティング、
任意選択的に、前記コーティングが、腸溶性コーティングである、
並びに/又は
1つ以上のさらなる有効成分。 - (i)前記経口固体剤形が、カプセルの形態であり、
任意選択的に、前記カプセルの外殻が、ゼラチン、ヒドロキシプロピルメチルセルロース又はデンプンから作られている、又は
(ii)前記経口固体剤形が、錠剤の形態である、請求項1〜4のいずれか一項に記載の経口固体剤形。 - 式A:
(a)少なくとも以下の約11.2、12.5、13.2、14.5、及び16.3における特性X線粉末回折ピーク(CuKα線、°2θで表される)を示す前記式Aの化合物の固体形態を、結合剤と、任意選択的に、希釈剤、崩壊剤及び/又は界面活性剤とを含む顆粒化液と混合するステップ;
(b)ステップ(a)の分散液を顆粒化させて、顆粒を形成するステップ;
(c)前記顆粒を乾燥させるステップ;
(d)任意選択的に、ステップ(b)又は(c)の前記顆粒を、希釈剤、酸、界面活性剤及び/又は滑沢剤とブレンドして、ブレンドされた顆粒を形成するステップ;並びに
(e)前記顆粒又はブレンドされた顆粒を、固体経口剤形に圧縮又は充填するステップ
を含む方法。 - 前記顆粒化液が、水をさらに含み、及び/又は
ステップ(c)における乾燥させることが、45℃を超える温度、好ましくは、55℃を超える温度において実施され、及び/又は
ステップ(e)において、前記顆粒又はブレンドされた顆粒が、錠剤の形態の固体経口剤形に圧縮される、請求項6に記載の方法。 - 前記脂質賦形剤が、TPGS又はGelucire 44/14、好ましくは、TPGSであり、及び/又は
前記カプセルの外殻が、ゼラチン、ヒドロキシプロピルメチルセルロース又はデンプンから作られている、請求項8に記載の方法。 - 請求項6〜10のいずれか一項に記載の方法により得られる経口固体剤形。
- (i)前記式Aの化合物の固体形態が、図1aに示されたX線粉末回折パターンと実質的に同じX線粉末回折パターンを有し、及び/又は
(ii)前記式Aの化合物の固体形態が、そのDSCサーモグラムにおいて151±3℃の吸熱ピークを示し、及び/又は
前記式Aの化合物の固体形態が、図3に示されたDSCサーモグラムと実質的に同じDSCサーモグラムを有する、請求項1〜5のいずれか一項に記載の経口固体剤形又は請求項6〜10のいずれか一項に記載の方法。 - 治療における使用のための、請求項1〜5及び11のいずれか一項に記載の経口固体剤形。
- 血漿カリクレインにより媒介される疾患又は状態の処置における使用のための、請求項1〜5及び11のいずれか一項に記載の経口固体剤形であって、
(i)前記血漿カリクレインにより媒介される疾患又は状態が、視力障害、糖尿病網膜症、糖尿病網膜症に伴う網膜血管透過性、糖尿病性黄斑浮腫、遺伝性血管性浮腫、網膜静脈閉塞症、糖尿病、膵炎、脳出血、腎症、心筋症、神経障害、炎症性腸疾患、関節炎、炎症、敗血症性ショック、低血圧症、がん、成人呼吸促迫症候群、播種性血管内凝固、心血管バイパス手術中の血液凝固及び外科術後の出血から選択され、又は
(ii)前記血漿カリクレインにより媒介される疾患又は状態が、糖尿病網膜症に伴う網膜血管透過性、糖尿病性黄斑浮腫及び遺伝性血管性浮腫から選択され、又は
(iii)前記血漿カリクレインにより媒介される疾患又は状態が、糖尿病網膜症に伴う網膜血管透過性及び糖尿病性黄斑浮腫から選択され、又は
(iv)前記血漿カリクレインにより媒介される疾患又は状態が、糖尿病性黄斑浮腫である、
経口固体剤形。 - 前記血漿カリクレインにより媒介される疾患又は状態が、遺伝性血管性浮腫である、請求項14に記載の使用のための経口固体剤形。
- 前記血漿カリクレインにより媒介される疾患又は状態が、糖尿病性黄斑浮腫である、請求項14に記載の使用のための経口固体剤形。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762592242P | 2017-11-29 | 2017-11-29 | |
US62/592,242 | 2017-11-29 | ||
GB1721515.3 | 2017-12-21 | ||
GBGB1721515.3A GB201721515D0 (en) | 2017-12-21 | 2017-12-21 | Dosage forms comprising a plasma kallikrein inhibtor |
PCT/GB2018/053443 WO2019106361A1 (en) | 2017-11-29 | 2018-11-28 | Dosage forms comprising a plasma kallikrein inhibitor |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2021504312A JP2021504312A (ja) | 2021-02-15 |
JP2021504312A5 true JP2021504312A5 (ja) | 2022-01-04 |
JPWO2019106361A5 JPWO2019106361A5 (ja) | 2022-03-07 |
JP7078722B2 JP7078722B2 (ja) | 2022-05-31 |
Family
ID=72846742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020526986A Active JP7078722B2 (ja) | 2017-11-29 | 2018-11-28 | 血漿カリクレイン阻害剤を含む剤形 |
Country Status (17)
Country | Link |
---|---|
US (1) | US11234939B2 (ja) |
JP (1) | JP7078722B2 (ja) |
CY (1) | CY1125227T1 (ja) |
DK (1) | DK3716952T3 (ja) |
ES (1) | ES2909893T3 (ja) |
HR (1) | HRP20220367T1 (ja) |
HU (1) | HUE057912T2 (ja) |
IL (1) | IL274557B1 (ja) |
LT (1) | LT3716952T (ja) |
MD (1) | MD3716952T2 (ja) |
MX (1) | MX2020005168A (ja) |
PL (1) | PL3716952T3 (ja) |
PT (1) | PT3716952T (ja) |
RS (1) | RS63069B1 (ja) |
RU (1) | RU2020121151A (ja) |
SI (1) | SI3716952T1 (ja) |
ZA (1) | ZA202003899B (ja) |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
US5786328A (en) | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
US7101878B1 (en) | 1998-08-20 | 2006-09-05 | Agouron Pharmaceuticals, Inc. | Non-peptide GNRH agents, methods and intermediates for their preparation |
PL215901B1 (pl) | 1999-04-15 | 2014-02-28 | Bristol Myers Squibb Co | Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek |
CA2463975A1 (en) | 2001-10-26 | 2003-05-01 | Maria Emilia Di Francesco | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
ATE455104T1 (de) | 2001-11-01 | 2010-01-15 | Icagen Inc | Pyrazolamide zur anwendung in der behandlung von schmerz |
GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
KR100755577B1 (ko) | 2002-04-26 | 2007-09-12 | 일라이 릴리 앤드 캄파니 | 타키키닌 수용체 길항제로서의 트리아졸 유도체 |
EP1426364A1 (en) | 2002-12-04 | 2004-06-09 | Aventis Pharma Deutschland GmbH | Imidazole-derivatives as factor Xa inhibitors |
DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
AU2004209456A1 (en) | 2003-02-03 | 2004-08-19 | Janssen Pharmaceutica N.V. | Quinoline-derived amide modulators of vanilloid VR1 receptor |
KR101471732B1 (ko) | 2003-08-27 | 2014-12-16 | 옵쏘테크 코포레이션 | 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법 |
TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
CA2578880C (en) | 2004-09-03 | 2013-01-29 | Yuhan Corporation | Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof |
WO2006091459A2 (en) | 2005-02-24 | 2006-08-31 | Joslin Diabetes Center, Inc. | Compositions and methods for treating vascular permeability |
GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
KR101142363B1 (ko) | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
ZA200800901B (en) | 2005-07-14 | 2010-05-26 | Takeda San Diego Inc | Histone deacetylase inhibitors |
US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
GB0606876D0 (en) | 2006-04-05 | 2006-05-17 | Glaxo Group Ltd | Compounds |
US20070258976A1 (en) | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
KR101398264B1 (ko) | 2006-07-06 | 2014-05-26 | 글락소 그룹 리미티드 | P2x7수용체 길항제로서의 치환된 n페닐메틸5옥소프롤린2아미드 및 그의 사용 방법 |
WO2008016883A2 (en) | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
MY147780A (en) | 2006-12-29 | 2013-01-31 | Abbvie Deutschland | Carboxamide compounds and their use as calpain inhibitors |
WO2008091692A2 (en) | 2007-01-25 | 2008-07-31 | Joslin Diabetes Center, Inc. | Methods of diagnosing, treating, and preventing increased vascular permeability |
EP2139887A2 (en) | 2007-03-07 | 2010-01-06 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
PT2142516E (pt) | 2007-03-30 | 2013-03-07 | Sanofi Sa | Compostos de hidrazida de pirimidina como inibidores de pgds |
EA200970912A1 (ru) | 2007-04-03 | 2010-02-26 | Глэксо Груп Лимитед | Карбоксамидные производные имидазолидина в качестве модуляторов p2x7 |
US8324263B2 (en) | 2007-07-26 | 2012-12-04 | Syngenta Crop Protection, Llc | Microbiocidally active carboxamides |
BRPI0815668A2 (pt) | 2007-08-22 | 2017-05-23 | Allergan Inc | compostos pirrol tendo atividade biológica antagonista e agonista de receptor de esfingosina-1-fosfato. |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
WO2009083553A1 (en) | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
EP2259679A4 (en) | 2008-01-31 | 2011-09-14 | Joslin Diabetes Ct | METHOD FOR THE TREATMENT OF CALLIQUE CLEANING DISORDERS |
WO2009106980A2 (en) | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
CN102026996B (zh) | 2008-03-13 | 2015-01-07 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的哒嗪衍生物 |
AU2009269178B2 (en) | 2008-07-08 | 2012-09-06 | Daiichi Sankyo Company, Limited | Nitrogen-containing aromatic heterocyclyl compound |
US8324385B2 (en) | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
WO2011075684A1 (en) | 2009-12-18 | 2011-06-23 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
JP2011157349A (ja) | 2010-01-07 | 2011-08-18 | Daiichi Sankyo Co Ltd | 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物 |
WO2011094496A2 (en) | 2010-01-28 | 2011-08-04 | The Medicines Company | Trypsin-like serine protease inhibitors, and their preparation and use |
JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
ES2483802T3 (es) | 2010-07-07 | 2014-08-07 | The Medicines Company (Leipzig) Gmbh | Inhibidores de serina proteasa |
US20130210809A1 (en) | 2010-07-14 | 2013-08-15 | Christelle Boléa | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
EP2458315B1 (de) | 2010-11-25 | 2017-01-04 | Balcke-Dürr GmbH | Regenerativer Wärmetauscher mit zwangsgeführter Rotordichtung |
EP2697196A1 (en) | 2011-04-13 | 2014-02-19 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
US9133128B2 (en) | 2011-06-17 | 2015-09-15 | Research Triangle Institute | Pyrazole derivatives as cannabinoid receptor 1 antagonists |
GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
EP2760829B1 (en) | 2011-09-27 | 2016-05-18 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
WO2013049096A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
EP2807157A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
WO2013111107A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | Aminopyridine derivatives as plasma kallikrein inhibitors |
NZ628762A (en) | 2012-02-10 | 2016-07-29 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9846160B2 (en) | 2012-02-27 | 2017-12-19 | Board Of Regents, The University Of Texas Systems | Ganglioside GD2 as a marker and target on cancer stem cells |
GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
US9045486B2 (en) | 2013-01-08 | 2015-06-02 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
GB201300304D0 (en) * | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
RS57890B1 (sr) | 2013-01-20 | 2019-01-31 | Dyax Corp | Procena i tretman poremećaja posredovanih bradikininom |
NZ711064A (en) | 2013-03-15 | 2019-06-28 | Verseon Corp | Pyridone-substituted pyrazolyl compounds as serine protease inhibitors |
MX363689B (es) | 2013-05-23 | 2019-03-29 | Kalvista Pharmaceuticals Ltd | Derivados de heterociclicos. |
GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
CN105683179B (zh) | 2013-08-14 | 2018-10-26 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶的抑制剂 |
KR20160106627A (ko) | 2013-12-30 | 2016-09-12 | 라이프에스씨아이 파마슈티컬스, 인크. | 치료적 억제 화합물 |
US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
NZ724250A (en) | 2014-03-07 | 2022-02-25 | Biocryst Pharm Inc | Human plasma kallikrein inhibitors |
WO2015171527A1 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
WO2015171526A2 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Tricyclic pyrazolopyridine compounds |
MX2017000450A (es) | 2014-07-16 | 2017-08-16 | Lifesci Pharmaceuticals Inc | Compuestos terapeuticos inhibidores. |
JP6824876B2 (ja) | 2014-08-22 | 2021-02-03 | バイオクライスト ファーマシューティカルズ, インコーポレイテッド | アミジン誘導体組成物及びそれらの使用 |
WO2016044662A1 (en) | 2014-09-17 | 2016-03-24 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
HUE060104T2 (hu) | 2015-02-27 | 2023-01-28 | Verseon Int Corporation | Szubsztituált pirazol vegyületek mint szerinproteázinhibitorok |
EP3317241A4 (en) | 2015-07-01 | 2019-01-23 | Lifesci Pharmaceuticals, Inc. | THERAPEUTIC INHIBITOR COMPOUNDS |
WO2017001926A2 (en) | 2015-07-01 | 2017-01-05 | Lifesci Pharmaceuticals, Inc | Therapeutic inhibitory compounds |
EP3368524B1 (en) | 2015-10-27 | 2021-08-18 | Boehringer Ingelheim International GmbH | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
JP6917988B2 (ja) | 2015-10-27 | 2021-08-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体 |
JP6884801B2 (ja) | 2016-05-31 | 2021-06-09 | カルビスタ・ファーマシューティカルズ・リミテッド | 血漿カリクレインインヒビターとしてのピラゾール誘導体 |
GB201609519D0 (en) | 2016-05-31 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide |
GB201609602D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
WO2019106359A1 (en) | 2017-11-29 | 2019-06-06 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
GB201719882D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
-
2018
- 2018-11-28 IL IL274557A patent/IL274557B1/en unknown
- 2018-11-28 RS RS20220166A patent/RS63069B1/sr unknown
- 2018-11-28 PT PT188152938T patent/PT3716952T/pt unknown
- 2018-11-28 JP JP2020526986A patent/JP7078722B2/ja active Active
- 2018-11-28 MD MDE20201002T patent/MD3716952T2/ro unknown
- 2018-11-28 US US16/767,803 patent/US11234939B2/en active Active
- 2018-11-28 PL PL18815293T patent/PL3716952T3/pl unknown
- 2018-11-28 ES ES18815293T patent/ES2909893T3/es active Active
- 2018-11-28 DK DK18815293.8T patent/DK3716952T3/da active
- 2018-11-28 HR HRP20220367TT patent/HRP20220367T1/hr unknown
- 2018-11-28 SI SI201830613T patent/SI3716952T1/sl unknown
- 2018-11-28 RU RU2020121151A patent/RU2020121151A/ru unknown
- 2018-11-28 LT LTEPPCT/GB2018/053443T patent/LT3716952T/lt unknown
- 2018-11-28 HU HUE18815293A patent/HUE057912T2/hu unknown
- 2018-11-28 MX MX2020005168A patent/MX2020005168A/es unknown
-
2020
- 2020-06-26 ZA ZA2020/03899A patent/ZA202003899B/en unknown
-
2022
- 2022-03-16 CY CY20221100207T patent/CY1125227T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6687248B2 (ja) | 回腸−空腸薬物送達用組成物 | |
KR100671275B1 (ko) | 미분된 에플러레논 조성물 | |
KR100645866B1 (ko) | 발데콕시브 조성물 | |
JP2022510732A (ja) | ニロチニブの医薬組成物 | |
KR101207618B1 (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
JP4970452B2 (ja) | メトホルミン徐放性錠剤およびその製造方法 | |
JP5351490B2 (ja) | ニフェジピン含有有核錠剤およびその製法 | |
KR20160045728A (ko) | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 | |
CA2656395C (en) | Immediate-release tablet formulations of a thrombin receptor antagonist | |
JP5479909B2 (ja) | 新規製剤 | |
US20080181946A1 (en) | Controlled Release Delivery System For Metformin | |
JP2010519201A (ja) | シロスタゾールを含む制御放出製剤及びその製造方法 | |
JPWO2006080481A1 (ja) | マルチプルユニット型経口徐放性製剤及びその製造方法 | |
JPWO2008066102A1 (ja) | 徐放性製剤 | |
US20100136119A1 (en) | Controlled-release preparation containing cilostazol and process for the preparation thereof | |
JP2006501274A (ja) | オキシカルバゼピンおよびその誘導体の改良放出製剤 | |
JP2009529061A (ja) | 錠剤製剤およびプロセス | |
JP2012516299A (ja) | 有機化合物のガレヌス製剤 | |
WO2012020301A2 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
CA2804358A1 (en) | Pharmaceutical compositions containing vanoxerine | |
JP6141580B2 (ja) | ラノラジンおよびドロネダロンの医薬組成物 | |
JP2021504312A5 (ja) | ||
JP7448275B2 (ja) | オービットアジンフマル酸塩腸溶性ペレット、その調製方法及び使用 | |
CN110214008A (zh) | 一种非布司他控释组合物及其制备方法 | |
CN115518066A (zh) | 一种用于治疗抗凝血的药物组合物及应用 |